Literature DB >> 44235

SK&F 92657, a novel antihypertensive acting by precapillary vasodilatation and beta-adrenoreceptor blockade.

E M Taylor, A M Roe, R A Slater.   

Abstract

1. The properties of a new antihypertensive agent, SK&F 92657, DL-3-[2-(3-t-butylamino-2-hydroxypropoxy)phenyl]-6-hydrazinopyridazine, have been studied. 2. The compound caused a sustained fall in blood pressure in several species as a result of precapillary vasodilatation, particularly in the renal and coronary vasculatures. 3. The beta-adrenoreceptor-blocking actions of SK&F 92657 prevent reflex cadiac stimulation.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 44235     DOI： 10.1042/cs057433s

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN： 0143-5221            Impact factor:   6.124


  12 in total

1.  Effects of carvedilol on renal function.

Authors:  A G Dupont
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Investigation of a combined arteriolar dilator and beta-adrenoceptor antagonist (SK & F 92657) in the peripheral vessels of man.

Authors:  J G Collier; D W Pitcher
Journal:  Br J Clin Pharmacol       Date:  1980-12       Impact factor: 4.335

3.  Cardiovascular effects in man of intravenous prizidilol hydrochloride (SK&F 92657); a new antihypertensive agent.

Authors:  W M Edmonstone; K K Manghani; A J Bell; M McLeod; G J Milton-Thompson; W L Burland
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

4.  An assessment of beta-adrenoceptor blockade in man by prizidilol hydrochloride.

Authors:  D W Pitcher; P V Curry; J R Trounce
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

5.  Acute effects of prizidilol on blood pressure, heart rate, catecholamines, renin and aldosterone in essential hypertension.

Authors:  M G Bianchetti; K Boehringer; P Weidmann; L Link; H Schiffl; W H Ziegler
Journal:  Eur J Clin Pharmacol       Date:  1982-10       Impact factor: 2.953

6.  Prizidilol (SK & F 92657), a new vasodilator with beta-blocking properties in the treatment of essential hypertension.

Authors:  T Lüscher; J Havelka; P Greminger; J Tuma; M Täuber; W Siegenthaler; W Vetter
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Comparison of prizidilol hydrochloride (SK & F 92657), a new antihypertensive agent with beta-adrenoceptor antagonist and vasodilator activity with propranolol and hydralazine in normal volunteers.

Authors:  J A Steiner; A Clancy; K K Manghani; I M James
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

8.  Metal binding by pharmaceuticals. Part 4. A comparative investigation of the interaction of metal ions with hydralazine, prizidilol and related compounds.

Authors:  H Al-Falahi; P M May; A M Roe; R A Slater; W J Trott; D R Williams
Journal:  Agents Actions       Date:  1984-01

9.  Pulmonary effects in man of oral prizidilol hydrochloride (SK&F 92657), a new antihypertensive agent.

Authors:  W M Edmondstone; J F Waller; K K Manghani; P L Hill; A J Bell; D M Denison
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

10.  Cardiovascular response to exercise and regional haemodynamics during treatment with prizidilol hydrochloride (SK & F 92 657) in moderately severe essential hypertension.

Authors:  O Andersson; S Ljungman; G Berglund
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.